Association of plasma brain-derived neurotrophic factor with Alzheimer’s disease and its influencing factors in Chinese elderly population

Fuqiang Qian1, Jian Liu2, Hongyu Yang3, Haohao Zhu1, Zhiqiang Wang1, Yue Wu1 and Zaohuo Cheng1*

1The Affiliated Wuxi Mental Health Center of Jiangnan University, Wuxi Central Rehabilitation Hospital, Wuxi, China, 2Hangzhou Seventh People’s Hospital, Hangzhou, China, 3Shanghai Mental Health Center, Shanghai, China

Objective: To explore the association of plasma brain-derived neurotrophic factor (BDNF) levels with Alzheimer’s disease and its influencing factors.

Materials and methods: A total of 1,615 participants were included in the present study. Among all subjects, 660 were cognitive normal controls (CNCs), 571 were mild cognitive impairment (MCI) patients, and 384 were dementia with Alzheimer’s type (DAT) patients. BDNF in blood samples collected from these subjects was analyzed via the Luminex assay. Additionally, DNA extraction and APOE4 genotyping were performed on leukocytes using a blood genotyping DNA extraction kit. All data were processed with SPSS 20.0 software. Analysis of variance (ANOVA) or analysis of covariance (ANCOVA) was used to compare differences among groups on plasma BDNF. Pearson and Spearman correlation analysis examined the correlation between BDNF and cognitive impairment, and linear regression analysis examined the comprehensive effects of diagnosis, gender, age, education, and sample source on BDNF.

Results: BDNF levels in DAT patients were higher than those in CNC and MCI patients ($P < 0.01$). BDNF levels were significantly correlated with CDR, MMSE, and clinical diagnosis ($P < 0.001$). Age, education, occupation, and sample source had significant effects on BDNF differences among the CNC, MCI, and DAT groups ($P < 0.001$). BDNF first decreased and then increased with cognitive impairment in the ApoE4-negative group ($P < 0.05$).

Conclusion: Plasma BDNF levels decreased in the MCI stage and increased in the dementia stage and were affected by age, education, occupation, and sample source. Unless the effects of sample heterogeneity and methodological differences can be excluded, plasma BDNF is difficult to become a biomarker for the early screening and diagnosis of AD.

KEYWORDS
Alzheimer’s disease, biomarker, BDNF, influencing factors, elderly population
Introduction

With the growth and longevity of the elderly population, Alzheimer’s disease (AD) has become a global human health problem. The Seventh China National Census reported that there were 264 million elderly people over 60 years old in China in 2020. By a prevalence of 4%, it is estimated that there will be more than 10 million AD patients in 2020, 20 million in 2035, and 40 million in 2060 (Cheng, 2020; Zhao and Li, 2020). AD is a chronic progressive and irreversible neurodegenerative disease (Alzheimer Association, 2017; Knopman et al., 2021). When AD progresses to the dementia stage, there are no disease-modifying drugs to prevent or reverse the disease process (Yiannopoulou and Papageorgiou, 2020). Therefore, early diagnosis and intervention of AD is particularly important. Many researchers are committed to looking for early diagnosis markers of AD, and brain-derived neurotrophic factor (BDNF) is one of the targets (Cheng et al., 2018; Rehiman et al., 2020).

Brain-derived neurotrophic factor plays an important role in brain development, neuroplasticity, and neuronal survival and its effects on neuronal transmission in the hippocampus, cerebral cortex, and basal forebrain are associated with learning and memory processes in the mature brain (Popova and Naumenko, 2019). Growing evidence indicates that changes in cerebral BDNF levels and the BDNF-TrkB signaling pathway may be involved in the etiopathogenesis of AD and that serum and brain BDNF levels are correlated. This evidence suggests that blood BDNF could be used as a biomarker for AD diagnosis, prognosis, and treatment monitoring (Ng et al., 2019; Marta et al., 2020; Mori et al., 2021).

Several recent meta-analyses analyzed the association between BDNF and AD cognitive impairment and found that the results are inconsistent or even contradictory, and higher, lower, or similar levels of circulating BDNF have all been reported in AD or MCI patients compared to healthy controls (Qin et al., 2017; Ng et al., 2019; Xie et al., 2020; Ma et al., 2022). For example, Kim et al. (2017) showed that blood BDNF levels seem to be increased in early AD and decreased in AD patients with low MMSE scores (Kim et al., 2017). Ng et al. (2019) reported that blood BDNF did not change in the MCI stage and only decreased in the late stage of AD. Not only are the conclusions of the difference in BDNF between AD patients and normal controls inconsistent, but there are also great differences in BDNF levels among different studies. Some studies reported that BDNF levels were very low (<5 pg/ml) (Nascimento et al., 2014; Wang et al., 2015), while others reported that BDNF levels were very high (>50 ng/ml) (Liu et al., 2015; Zhang et al., 2019).

These contradictory results may be related to sample heterogeneity (age, gender, education, condition, comorbidity, and medication) and methodological differences (cognitive rating tools and diagnostic criteria, sample type, blood processing, storage duration, etc.) (Balietti et al., 2018); for instance, blood BDNF decreased with age or weight in elderly individuals (Glud et al., 2019), increased in the early AD stage and decreased in the late stage (Laske et al., 2006). It is very important to study and control the influence of these factors on the association between BDNF levels and cognitive impairment, and it is more important to consider the possible influence of various factors in the interpretation of results. This study investigated the association of plasma BDNF levels with cognitive impairment and its influencing factors.

Materials and methods

Participants

This study recruited adult and elderly volunteers over 50 years old from communities and mental health hospitals in four cities with different levels (Shanghai, Hangzhou, Wuxi, Jiangyin). The unified training, containing the purpose, content, and methods, was organized to ensure the comparability of the procedures. All subjects received clinical interviews and examinations, relevant cognitive evaluations, necessary laboratory or imaging examinations, and overnight fasting venous blood was collected. Based on interviews, assessments and examinations, 1,615 valid samples were obtained after excluding serious physical, neurological and mental disorders that may cause cognitive impairment (including uncontrolled hypertension, diabetes, Parkinson’s disease, cerebrovascular disease, hypothyroidism, schizophrenia, depression, etc.), including 230 persons in Shanghai, 248 in Hangzhou, 937 in Wuxi, and 200 in Jiangyin. According to the NINCDS-ADRDA criteria (McKhann et al., 1984) for dementia with Alzheimer’s type (DAT), DSM-5 criteria (American Psychiatric Association, 2013) for neurocognitive impairment and Petersen criteria (Petersen et al., 1999) for mild cognitive impairment (MCI), 1,615 participants were clinically diagnosed into three groups: 660 cognitive normal controls (CNCs), 571 MCI patients and 384 DAT patients, of which 218 DAT patients were from outpatients and inpatients in mental health hospitals, and other DAT patients and CNC and MCI subjects were from community volunteers. Sample sources and basic information are shown in Table 1.

This study was approved by the ethics committee of Wuxi Mental Health Center, the ethics committee of Shanghai Mental Health Center and the ethics committee of Hangzhou Seventh People’s Hospital. According to the Declaration of Helsinki, all subjects or their caregivers were informed of the procedure and signed informed consent was obtained before participating in the study.
Clinical interview and examination

Clinical interviews and examinations included four primary sections. (A) Social demographic data: name, gender, age, nationality, marriage, education, occupation, family structure, economic status, smoking and drinking habits, outdoor activities, etc.; (B) Medical history and mental examination: memory and cognitive impairment, mental status examination, family history, past medical history and individual medication; (C) Physical examination: general examination, such as heart rate, blood pressure, height, weight, vision, hearing, hair color, and facial plaques, etc., emphasis on neurological examination, such as sensory symmetry, motor function, muscle strength, muscle tone, language function, gait and balance, tremor. (D) Necessary auxiliary examination: ECG, EEG, brain CT, blood biochemistry tests, etc. Only the corresponding author (ZC) could obtain the details of each parameter of the patients. The cognitive test interviewers were only responsible for the scale assessment.

Psychological and neurocognitive assessment

Assessments involved three important aspects: subjective cognitive impairment screening, objective cognitive impairment assessment, and related mental rating. Subjective cognitive impairment of elderly volunteers in the communities was screened using Brief Elderly Cognitive Screening Questionnaire Screening (BECSI) (Wu et al., 2016), with a total score of more than four points indicating subjective cognitive impairment. Overall objective cognitive impairments were assessed by the Clinical Dementia Rating (CDR) (Academy of Cognitive Disorder of China, 2018), Alzheimer’s Dementia Assessment Scale-cognitive subscale (ADAS-cog) (Wang et al., 2000), and/or Mini Mental State Examination (MMSE) (Li et al., 1988). The cognitive function level of each subject was determined by the cutoff score of each scale (CDR: 0 points for normal cognition, 0.5 for mild cognitive impairment, ≥1 for severe cognitive impairment; ADAS-cog: 0–9 for normal cognition, 10–15 for mild cognitive impairment, ≥ 16 points for severe cognitive impairment, or MMSE: 28–30 for normal cognition, 20–27 for mild cognitive impairment, <20 for severe cognitive impairment). Other related mental ratings included the Activity of Daily Living Scale (ADL) (Lawton and Brody, 1969), Hachinski Ischemic Scale (HIS) (Fan, 1990) and Hamilton Depression Scale (HAMD) (Zhao and Zheng, 1992).

Plasma brain-derived neurotrophic factor assays and APOE genotyping

Blood samples were collected in anticoagulant tubes with 2% EDTA in the morning after an overnight fast. Blood samples were centrifuged at 3,000 rpm (1,000 × g) for 30 min at 4°C. Plasma and leukocytes were collected in plastic vials and stored at −80°C for further analyses. Only the corresponding author (ZC) could obtain the details of each parameter of the patients. The blood lab analysis staff was blinded to other results, since the patients were represented by numbers.

Luminex assays

Protein detection was entrusted to Nanjing University of Technology (laboratory certificated Millipore Shanghai Trading Co., Ltd., based on Milliplex technology). The Luminex kit (Milliplex Catalog ID. HNDG3MAG-36K-04. Neu) were obtained from Millipore (Billerica, MA, USA), and assays were performed according to the manufacturer’s instructions to determine the plasma levels of multiple proteins, including BDNF (pg/mL). Properly diluted plasma samples were incubated with the antibody-coupled microspheres and then with biotinylated detection antibody before the addition of streptavidin-phycoerythrin. The captured bead complexes were measured with a FLEXMAP 3D system (Luminex Corporation, Austin, TX, USA) using the following instrument settings (events/bead, 50; sample size, 50 µL; discriminator gate, 8,000–15,000). The raw data (mean fluorescence intensity) were collected and further processed to calculate the protein concentration. Before statistical analysis, we examined the performance of each assay using quality checks (QC). Median fluorescent intensity (MFI) was measured using xPONENT 5.1 (Luminex Corporation) and exported into Milliplex Analyst

### TABLE 1 Sample source and basic data.

| Parameter                | Wuxi                  | Jiangyi               | Hangzhou              | Shanghai              | Total sample | \( \chi^2 \) or F | P       |
|--------------------------|-----------------------|-----------------------|-----------------------|-----------------------|--------------|------------------|---------|
| Gender (male/female)     | 432/505               | 86/114                | 87/161                | 73/157                | 678/937      | 21.380           | <0.001  |
| Age (years)              | 70.09 ± 9.33          | 67.89 ± 7.83          | 67.46 ± 8.16          | 77.98 ± 9.40          | 78.53 ± 7.03 | 189.968          | <0.001  |
| Education (years)        | 7.96 ± 4.07           | 9.41 ± 3.12           | 7.63 ± 2.71           | 5.58 ± 4.57           | 4.88 ± 4.89  | 140.581          | <0.001  |
| Diagnosis (HC/MCI/DAT)   | 660/571/384           | 476/281/180           | 33/139/28             | 50/49/19              | 101/102/27   | 341.868          | <0.001  |
| CDR-GS (score)           | 0.61 ± 0.70           | 0.55 ± 0.68           | 0.60 ± 0.63           | 0.99 ± 0.84           | 0.44 ± 0.54  | 32.576           | <0.001  |
| BDNF (pg/mL)             | 10555.7 ± 12135.1     | 10373.5 ± 9646.3      | 3632.0 ± 5605.6       | 24976.2 ± 16152.4     | 1769.4 ± 2028.5 | 267.081          | <0.001  |
| Ln(X + 1)                | 8.55 ± 4.00           | 8.82 ± 4.05           | 7.51 ± 1.29           | 9.79 ± 1.17           | 7.01 ± 0.97  | 338.724          | <0.001  |
5.1 (VigeneTech, Carlisle, MA, USA) for estimation of protein concentrations using a five-parameter logistic fit. Briefly, all analysts that passed QC checks based on the following four criteria (standard curve linearity, intra-assay coefficient of variation, interassay coefficient of variation for reference sample, and percentage of missing data) were taken forward for further analysis.

**DNA extraction and APOE4 genotyping**

DNA extraction and APOE4 genotyping were performed by Wuxi Biowing Applied Biotechnology Co., Ltd. DNA was extracted from leukocytes using a blood genotyping DNA extraction kit (Tiangen Biotech, Beijing, China), and the APOE4 genotype was analyzed using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). According to the methods reported by Hixson and Vernier (1990), APOE4 gene primers were designed and synthesized, and PCR amplification, enzyme digestion, and APOE4 genotyping were performed. The three alleles were grouped into six genotypes, which were APOE4 negative (E2/E2, E3/E3, E2/E3) and APOE4 positive (E2/E4, E3/E4, E4/E4).

**Data processing and statistical analysis**

All data were processed with SPSS 20.0 software. Logarithmic transformation \[\ln(x + 1)\] of BDNF data was performed to approximate a normal distribution. Pearson's chi-square test was used to compare differences among groups on gender, marriage, family, occupation, and APOE4 genotypes. The F test was used to compare differences among groups for age, years of education, blood pressure, body mass index, psychological test scores and biochemical test results. Analysis of variance (ANOVA) or analysis of covariance (ANCOVA) was used to compare differences among groups on plasma BDNF. Pearson and Spearman correlation analysis examined the correlation between BDNF and cognitive impairment, and linear regression analysis examined the comprehensive effects of diagnosis, gender, age, education, and sample source on BDNF.

**Results**

**Comparison of demographic, clinical and laboratory data among the three groups**

The differences in the demographic, clinical and laboratory data among the CNC, MCI, and DAT groups are shown in Table 2. There were significant differences among the three groups in demographic data, such as sex, age, education, marital status, family type, and previous occupation \((P < 0.01)\). There were no significant differences in body mass index (BMI), systolic blood pressure (SBP) or diastolic blood pressure (DBP) among the groups \((P > 0.05)\). There were no significant differences among the three groups in biochemical indexes such as fasting blood glucose (FBG), triglycerides, thyroid stimulating hormone (TSH), free T4, folic acid and vitamin B12 \((P > 0.05)\), but there was a significant difference in laboratory indexes such as APOE genotype, total protein, albumin, total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), free T3 and BDNF \((P < 0.05)\). There were significant differences in cognitive evaluation scores such as ADAS-cog, MMSE, CDR-GS, and ADL \((P < 0.001)\).

**Relationship between plasma brain-derived neurotrophic factor and cognitive function**

The subjects were divided into four groups (CNC, MCI, mild dementia, and moderate-severe dementia) according to the CDR, MMSE or clinical diagnosis. The plasma BDNF differences among groups were compared by ANCOVA (age and education as covariates), and the correlation between BDNF and cognitive function was calculated by Pearson and Spearman correlation analysis. The results are shown in Table 3 and Figure 1. There was a significant difference in BDNF among the four groups \((P < 0.01)\). BDNF levels in dementia patients were higher than those in CNC and MCI patients \((P < 0.01)\), and there was no significant difference in BDNF between the CNC and MCI groups. BDNF levels were significantly correlated with CDR, MMSE, and clinical diagnosis \((P < 0.001)\). BDNF was positively correlated with CDR scores and clinical diagnosis, and negatively correlated with MMSE score.

**Factors influencing the association of brain-derived neurotrophic factor with cognitive impairment**

The results of ANCOVA and ANOVA are shown in Table 4. Age, education, occupation and sample source had significant effects on BDNF differences among the CNC, MCI, and DAT groups \((P < 0.001)\), and sex and APOE4 had no significant effect on BDNF differences among the groups \((P > 0.05)\). The trend of the BDNF expression was the same in different genders with significant difference \((P = 0.000)\), which decreased in MCI and increased in DAT. BDNF first decreased and then increased significantly with the aggravation of cognitive impairment in groups aged 51–64 and 65–74 \((P < 0.05)\), and BDNF increased gradually with cognitive impairment in the group over 75 years old \((P < 0.05)\). BDNF increased gradually with cognitive impairment in the group with 0–6 years of education \((P < 0.05)\), and there was no significant change in BDNF with cognitive impairment.
TABLE 2  Demographic, clinical and laboratory data and cognitive scores of the three groups.

|                        | Total sample  | CNC (n = 660) | MCI (n = 571) | DAT (n = 384) | \( \chi^2 \) or F-value | P-value  \\
|------------------------|---------------|---------------|---------------|---------------|--------------------------|----------
| Gender (Male/Female)   | 678/937       | 306/354       | 229/342       | 143/241       | 9.574                    | 0.008    \\
| Age (years)           | 70.09 ± 9.33  | 68.21 ± 8.26  | 69.91 ± 8.74  | 77.00 ± 9.19  | 130.867                  | <0.001   \\
| Education (years)     | 7.96 ± 4.07   | 9.49 ± 3.59   | 7.44 ± 3.73   | 6.11 ± 4.37   | 101.896                  | <0.001   \\
| Marriage (in marriage/other) | 1383/232     | 598/62        | 490/81        | 255/129       | 21.967                   | <0.001   \\
| Family (Big family/Couple/Others) | 568/864/183   | 243/385/32    | 218/315/38    | 107/164/113   | 131.930                  | <0.001   \\
| Occupation (Physical/Technical/Intellectual) | 197/1072/346 | 43/416/201    | 134/363/74    | 20/293/71     | 116.592                  | <0.001   \\
| BMI (kg/m\(^2\))      | 23.85 ± 3.11  | 23.74 ± 2.92  | 24.07 ± 3.29  | 23.51 ± 3.25  | 1.848                    | 0.156    \\
| SBP (mm/Hg)           | 136.25 ± 16.76| 135.87 ± 16.47| 135.91 ± 16.40| 139.76 ± 19.45| 2.233                    | 0.108    \\
| Total cholesterol (mmol/L) | 5.12 ± 1.02 | 5.17 ± 0.97   | 5.15 ± 1.09   | 4.81 ± 0.90   | 4.981                    | 0.007    \\
| HDL (mmol/L)          | 2.95 ± 0.74   | 3.02 ± 0.74   | 2.93 ± 0.75   | 2.64 ± 0.65   | 10.307                   | <0.001   \\
| LDL (mmol/L)          | 1.29 ± 0.31   | 1.19 ± 0.31   | 1.29 ± 0.31   | 1.22 ± 0.33   | 8.533                    | <0.001   \\
| Albumin (g/L)         | 4.6 ± 2.96    | 4.60 ± 2.82   | 4.75 ± 2.99   | 4.60 ± 1.38   | 13.236                   | <0.001   \\
| Triglyceride (mmol/L) | 1.66 ± 1.31   | 1.66 ± 1.08   | 1.63 ± 1.30   | 1.81 ± 2.19   | 0.737                    | 0.473    \\
| APOE4 (Positive/Negative) | 176/795     | 80/387        | 59/330        | 37/778        | 17.899                   | <0.001   \\
| Total protein (g/L)   | 75.27 ± 4.91  | 75.68 ± 4.93  | 74.98 ± 4.72  | 74.31 ± 4.61  | 4.292                    | 0.014    \\
| TSH (mIU/L)           | 2.33 ± 20.8   | 2.24 ± 1.65   | 2.36 ± 1.82   | 2.75 ± 4.54   | 1.862                    | 0.156    \\
| FreeT3 (pmol/L)       | 4.77 ± 1.55   | 4.98 ± 1.39   | 4.42 ± 1.53   | 4.92 ± 2.83   | 13.707                   | <0.001   \\
| FFA (mmol/L)          | 51.2 ± 1.02   | 5.17 ± 0.97   | 5.15 ± 1.09   | 4.81 ± 0.90   | 4.981                    | 0.007    \\
| Vitamin B12 (pmol/L)  | 350.01 ± 198.01 | 356.73 ± 282.76 | 345.94 ± 189.65 | 327.82 ± 201.96 | 0.902                    | 0.406    \\
| CDR-GS (score)        | 6.10 ± 0.70   | 0.18 ± 0.28   | 0.50 ± 0.22   | 1.50 ± 0.86   | 573.035                  | <0.001   \\
| ADAS-cog (score)      | 9.38 ± 6.22   | 6.16 ± 2.56   | 11.48 ± 5.26  | 20.25 ± 11.05 | 326.625                  | <0.001   \\
| MMSE (score)          | 19.46 ± 8.88  | 27.40 ± 3.35  | 23.33 ± 4.29  | 10.72 ± 7.01  | 754.315                  | <0.001   \\
| ADL (score)           | 18.48 ± 13.04 | 13.67 ± 5.74  | 14.85 ± 6.68  | 33.95 ± 18.48 | 417.864                  | <0.001   \\
| BDNF Mean ± SD (pg/mL) | 10555.7 ± 12135.51 | 10101.6 ± 11748.3 | 8556.3 ± 10255.5 | 14309.1 ± 14356.8 | 27.452                  | <0.001   \\
| Ln(X + 1)             | 8.55 ± 1.40   | 8.50 ± 1.41   | 8.32 ± 1.39   | 8.98 ± 1.29   | 27.302                   | <0.001   \\

TABLE 3  Association between BDNF and cognitive function.

|                     | CNC (n = 660) | MCI (n = 571) | Mild dementia | Moderate-severe dementia | ANCOVA Bonferroni test | Pearson correlation | Spearman correlation |
|---------------------|---------------|---------------|---------------|--------------------------|------------------------|--------------------|---------------------|
| CDR group          | 8.35 ± 1.39   | 8.53 ± 1.40   | 8.85 ± 1.28   | 8.89 ± 1.38              | F = 17.783, P = 0.000  | r = 0.124           | r_s = 0.124          |
| (n = 486)           | (n = 778)     | (n = 164)     | (n = 187)     |                          |                        |                    |                     |
| MMSE group         | 8.14 ± 1.70   | 8.01 ± 1.57   | 8.57 ± 1.46   | 8.86 ± 1.45              | F = 12.632, P = 0.000  | r = −0.183          | r_s = 0.183          |
| (n = 236)           | (n = 269)     | (n = 182)     | (n = 172)     |                          |                        |                    |                     |
| Clinical diagnosis  | 8.50 ± 1.41   | 8.32 ± 1.39   | 9.08 ± 1.19   | 8.88 ± 1.38              | F = 26.667, P = 0.000  | r = 0.117           | r_s = 0.117          |
| (n = 660)           | (n = 571)     | (n = 198)     | (n = 186)     |                          |                        |                    |                     |

in the other two groups (P > 0.05). BDNF first decreased and then increased significantly with cognitive impairment in physical and technical occupation (P < 0.05), and BDNF increased gradually with cognitive impairment in intellectual occupation (P > 0.05). BDNF increased gradually with cognitive impairment in the Shanghai group (P = 0.010), and there was no significant change in cognitive impairment in other districts (P > 0.05). BDNF in the male and female groups first decreased and then increased significantly with cognitive impairment (P < 0.001). BDNF first decreased and then increased with cognitive impairment in the ApoE4-negative group (P < 0.05), and there was no significant change in
FIGURE 1
The correlations between Brain-Derived Neurotrophic Factor (BDNF) and Clinical Dementia Rating (CDR), Mini Mental State Examination (MMSE), and clinical diagnosis.

BDNF with cognitive impairment in the ApoE4-positive group ($P > 0.05$).

The combined effects of related factors on brain-derived neurotrophic factor

The combined effect of diagnosis, gender, age, education, and sample source on plasma BDNF was examined by ANCOVA and linear regression analysis, and detailed results are shown in Table 5. The effects of diagnosis, age and education on plasma BDNF were statistically significant ($P < 0.01$), but the gender effect was not statistically significant ($P = 0.149$), and only 5.1% of the variation could be explained. After adding the sample source, only the sample source and gender effects were statistically significant ($P < 0.05$), the effects of diagnosis, age and education were not statistically significant ($P > 0.05$), and the explained variation reached 37.9%. Linear regression analysis showed that the four factors could explain 3.0% of BDNF variation, of which the effects of diagnosis, age, and education were statistically significant ($P = 0.000$). Adding the sample source explained 38.0% of the BDNF variation; only the effects of sample source and sex were statistically significant ($P < 0.01$), and the effects of diagnosis, age and education were not statistically significant ($P > 0.05$).

Discussion

Growing evidence indicates that BDNF is associated with the pathophysiology of AD. However, the association of BDNF levels in the brain or peripheral blood with cognitive impairment in AD is quite complex and influenced by many factors, such as sample heterogeneity and methodological differences (Kim et al., 2017; Qin et al., 2017; Bialietti et al., 2018; Ng et al., 2019; Marta et al., 2020; Xie et al., 2020; Girotra et al., 2022). In the present study, the association of plasma BDNF with AD cognitive impairment and influencing factors was investigated in depth based on a large sample of elderly people in the community. It was preliminarily found that plasma BDNF concentrations were related to AD cognitive impairment but not a simple linear relationship. Since there were significant difference between CNC, MCI, and DAT cohorts regarding age, sex, education, and social status, the factors influencing the association between plasma BDNF and cognitive impairment were analyzed separately. The alterations in the plasma BDNF levels of AD depended on the stages or severity of AD and were affected by factors such as age, education or sample source. The main findings of this study are briefly analyzed and discussed as follows.

Many studies have found alterations in blood BDNF levels in patients with AD and MCI, but the results are inconsistent or even contradictory. Most studies observed a decrease in blood BDNF levels (Borba et al., 2016; Siuda et al., 2017; Zhang et al., 2019; Tang et al., 2020), a few reported an increase in BDNF concentrations (Lee et al., 2015; Ng et al., 2021), and other studies reported no significant change in BDNF levels (O’Bryant et al., 2011; Wang et al., 2015). Xie et al. (2020) meta-analysis showed that peripheral blood BDNF decreased gradually with the aggravation of cognitive impairment. Ng et al. (2019) meta-analysis showed that peripheral BDNF levels decreased in patients with AD and could only be detected at the late stage of the dementia spectrum. Qin et al. (2017) suggested that AD or MCI is accompanied by reduced peripheral blood BDNF levels, supporting an association between the decreasing levels of BDNF and the progression of AD.

In this study, BDNF levels in dementia patients were higher than those in MCI patients and cognitively normal elderly individuals in the total sample and most subsamples. Compared with normal elderly individuals, there were no significant BDNF alterations (higher or lower) in MCI patients in the total sample and most subsamples. From the change trend, BDNF showed three change patterns with cognitive impairment: (1) BDNF
### Table 4 Factors influencing the association between plasma BDNF and cognitive impairment.

| Relevant factors | CNC(A) | MCI(B) | DAT(C) | ANCOVA | ANOVA | LSD test |
|------------------|--------|--------|--------|---------|--------|----------|
| **Gender**       |        |        |        |         |        |          |
| Male             | 8.44 ± 1.34 | 8.28 ± 1.38 | 8.98 ± 1.25 | Group: F = 26.998 | F = 12.905 | C > A = B |
| (n = 306)        | (n = 229) | (n = 143) |        |         |        |          |
| Female           | 8.55 ± 1.46 | 8.35 ± 1.41 | 8.98 ± 1.31 | Gender: F = 1.182 | F = 14.411 | C > A = B |
| (n = 354)        | (n = 342) | (n = 241) |        |         |        |          |
| **Age**          |        |        |        |         |        |          |
| 51–64 years      | 8.76 ± 1.28 | 8.45 ± 1.35 | 8.92 ± 1.21 | Group: F = 37.030 | F = 4.019 | C > A = B |
| (n = 255)        | (n = 186) | (n = 47) |        |         |        |          |
| 65–74 years      | 8.68 ± 1.29 | 8.29 ± 1.38 | 9.03 ± 1.16 | Group: F = 11.513 | F = 11.513 | C > A = B |
| (n = 255)        | (n = 200) | (n = 95) |        |         |        |          |
| >75 years        | 7.75 ± 1.55 | 8.23 ± 1.45 | 8.98 ± 1.35 | F = 36.034 | F = 36.034 | C > B > A |
| (n = 150)        | (n = 185) | (n = 242) |        |         |        |          |
| **Education**    |        |        |        |         |        |          |
| 0–6 years        | 8.09 ± 1.54 | 8.12 ± 1.47 | 9.05 ± 1.23 | Group: F = 30.665 | F = 34.906 | C > A = B |
| (n = 136)        | (n = 276) | (n = 247) |        |         |        |          |
| 7–9 years        | 8.62 ± 1.33 | 8.46 ± 1.31 | 8.87 ± 1.32 | Group: F = 2.765 | F = 2.765 | C > A = B |
| (n = 277)        | (n = 207) | (n = 75) |        |         |        |          |
| >10 years        | 8.58 ± 1.38 | 8.63 ± 1.23 | 8.84 ± 1.45 | F = 0.994 | F = 0.994 | C > A = B |
| (n = 247)        | (n = 88) | (n = 50) |        |         |        |          |
| **Occupation**   |        |        |        |         |        |          |
| Physical         | 8.32 ± 1.24 | 7.81 ± 1.41 | 8.74 ± 1.37 | Group: F = 26.556 | F = 4.243 | C > B, A = B |
| (n = 37)         | (n = 110) | (n = 15) |        |         |        |          |
| Technical        | 8.88 ± 1.23 | 8.80 ± 1.22 | 9.39 ± 1.09 | Group: F = 17.803 | F = 17.803 | C > A = B |
| (n = 352)        | (n = 298) | (n = 218) |        |         |        |          |
| Intellectual     | 8.75 ± 1.30 | 8.98 ± 1.10 | 9.17 ± 1.21 | Group: F = 2.648 | F = 2.648 | C > A = B |
| (n = 170)        | (n = 61) | (n = 53) |        |         |        |          |
| **Sample sources** |      |        |        |         |        |          |
| Wuxi             | 8.79 ± 1.10 | 8.87 ± 1.03 | 8.84 ± 0.96 | Group: F = 0.405 | F = 0.523 | A = B = C |
| (n = 476)        | (n = 281) | (n = 180) |        |         |        |          |
| Jiangy           | 7.42 ± 1.13 | 7.56 ± 1.34 | 7.33 ± 1.21 | Group: F = 0.486 | F = 0.486 | A = B = C |
| (n = 33)         | (n = 139) | (n = 28) |        |         |        |          |
| Hangzhou         | 9.80 ± 1.75 | 9.91 ± 0.60 | 9.75 ± 1.09 | Group: F = 0.324 | F = 0.324 | A = B = C |
| (n = 50)         | (n = 49) | (n = 149) |        |         |        |          |
| Shanghai         | 6.82 ± 0.94 | 7.09 ± 0.99 | 7.41 ± 0.90 | Group: F = 4.278 | F = 4.278 | C > A = B |
| (n = 101)        | (n = 102) | (n = 27) |        |         |        |          |
| **APOE4**        |        |        |        |         |        |          |
| Negative         | 8.74 ± 1.15 | 8.43 ± 1.25 | 8.90 ± 1.04 | Group: F = 9.318 | F = 8.434 | C > A > B |
| (n = 387)        | (n = 330) | (n = 78) |        |         |        |          |
| Positive         | 8.63 ± 1.27 | 8.49 ± 1.39 | 8.91 ± 0.93 | Group: F = 1.231 | F = 1.231 | C > A = B |
| (n = 80)         | (n = 59) | (n = 37) |        |         |        |          |

Source: 896.678

Frontiers in Aging Neuroscience
decreased in the MCI stage and increased in the dementia stage. This pattern was observed in the total sample (clinical diagnosis and MMSE group) and subsamples (men and women, 51–64 years old and 65–74 years old group, physical and technical occupation, 7–9 years education group, and APOE4 negative and positive group); (2) BDNF increased gradually with cognitive impairment. This pattern was found in the CDR group, over 75 years old group, 0–6 years and more than 10 years of education group, intellectual occupation, and Shanghai sample; (3) Although the unified training has ensured the consistency of research methods, etc., the trend of BDNF values may be different due to regional differences. Therefore, after analyzing the trends in different centers, this study uses the overall trend to conduct a comparative study. As a result, BDNF increased in the MCI stage and decreased in the dementia stage. This pattern was found in Wuxi, Jiangyi, and Hangzhou samples. The three change patterns are supported by research evidence; for example, Woolley et al. (2012) and Forlenza et al. (2015) supported the pattern with BDNF decreasing early and subsequently increasing; Sonali et al. (2013) and Lee et al. (2015) studies supported the gradually increasing BDNF pattern. The results of Laske et al. (2006), Angelucci et al. (2010), and Faria et al. (2014) support the model in which BDNF first increases and then decreases.

These discrepancies might be explained by the heterogeneity of AD samples (Baietti et al., 2018) and BDNF compensatory mechanisms (Laske et al., 2006). BDNF plays an important role in the pathogenesis of AD (Song et al., 2015); with the progression of AD, brain-derived BDNF gradually decreases, and BDNF alterations in peripheral blood may be more complicated. In the early stage of MCI, peripheral blood BDNF can supplement BDNF deficiency in the brain through the blood–brain barrier (Pan et al., 1998; Klein et al., 2011), and peripheral blood BDNF may decrease slightly. In the late stage of MCI or early stage of dementia, the continuous decrease in BDNF may stimulate the compensatory mechanism (increased platelet-derived BDNF synthesis and release) (Fujimura et al., 2002), resulting in increased plasma BDNF levels, and in the late stage of dementia, compensatory failure will reduce blood BDNF levels.

A large number of studies suggest that blood BDNF could be used as a biomarker for AD diagnosis, prognosis, and treatment monitoring, but the survey results of blood BDNF levels in AD patients are very inconsistent (Bathina and Das, 2015; Song et al., 2015; Marta et al., 2020; Xie et al., 2020; Mori et al., 2021). There were not only differences in demographic data (such as sex, age and education) and disease status (stage, severity, medication or comorbidity) among different studies but also differences in demographic data between the AD group and the control group in the same study. The heterogeneity of these samples may be an important reason for the inconsistency of research results (Baietti et al., 2018).

Many studies have found that there are differences in blood BDNF levels by sex (women higher than men), age (decrease with age), plasma/serum (serum higher than plasma), disease stage (increase in the early stage and decrease in the late stage), cognitive impairment severity, depressive symptoms, medication and other factors that also affect blood BDNF levels (Lommatzsch et al., 2005; Laske et al., 2006; Fukumoto et al., 2010). In line with these findings, the present study found that plasma BDNF levels were affected by age, education, occupation and sample source, and BDNF differences among clinical diagnosis groups remained after excluding the influence of each covariate.

### TABLE 5 The comprehensive effects of diagnosis, gender, age, education and sample source on brain-derived neurotrophic factor.

| Related factors | ANCOVA | Linear regression |
|-----------------|---------|-------------------|
|                 | $\chi^2$ | F     | $P$ | $B$ | $\beta$ | t     | $P$ |
| Diagnosis       | 71.948  | 38.858 | <0.001 | 0.308 | 0.173 | 6.446 | <0.001 |
| Gender          | 3.864   | 2.087  | 0.149  | 0.11  | 0.039 | 1.536 | 0.125  |
| Age             | 38.854  | 20.984  | <0.001 | −0.172 | −0.100 | −3.817 | <0.001 |
| Education       | 14.019  | 7.572  | 0.006  | 0.167 | 0.095 | 3.504 | <0.001 |

$R^2 = 0.053$, Adjust $R^2 = 0.051$

$R^2 = 0.033$, Adjust $R^2 = 0.030$

$R^2 = 0.382$, Adjust $R^2 = 0.379$

$R^2 = 0.382$, Adjust $R^2 = 0.380$
In addition, demographic variables such as gender, age and education and clinical variables such as AD severity, disease stage and medication cannot only affect blood BDNF alone but also comprehensively affect BDNF through interactive or synergistic mechanisms. This study further examined the comprehensive impact of multiple factors on BDNF by ANCOVA and linear regression analysis. Four-factor analysis found that diagnosis, age and education had a significant impact on BDNF, which could explain only 3–5% of the variance. When the sample source variable was introduced, only the sample source and gender had significant effects on BDNF, and the explained variance reached 38%. It is worth noting that in this study, the sample source is not a simple variable. It includes not only demographic differences such as gender, age, education and occupation but also AD stage and severity, concomitant diseases and medication, blood sample processing and storage duration. These findings remind us that to make BDNF a biomarker of complex diseases such as AD, we must establish standardized detection methods and cut off values of BDNF according to the weight of each influencing factor.

Data availability statement

The dataset generated during and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics statement

The studies involving human participants were reviewed and approved by the Wuxi Mental Health Center. The patients/participants provided their written informed consent to participate in this study.

Author contributions

ZC designed the study, analyzed the data, and revised the manuscript. FQ and HY collected and drafted the manuscript. JL, HZ, and YW participated in the design of the study, data management, and analysis. ZW contributed to data collection management. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the Social Development Key Projects in Jiangsu Province (BE2015615), National Natural Science Foundation of China (No. 82104244), Wuxi Municipal Health Commission (Q202101), Wuxi Taihu Talent Project (Nos. WXTTP2020008 and WXTTP2021), and Wuxi Medical Development Discipline Project (No. FZXK2021012).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Academy of Cognitive Disorder of China (2018). The clinical dementia rating (simplified Chinese). Chin. J. Geriat. 37, 367–371.
Alzheimer Association (2017). Alzheimer’s disease facts and figures. Chicago, IL: Alzheimer Association.
American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorder, DSM-V. Washington, DC: American Psychiatric Association. doi: 10.1176/appi.books.9780890425596
Angelucci, F., Spalletta, G., di Iulio, F., Caramella, A., Salani, F., Varsi, A. E., et al. (2010). Alzheimer’s disease (AD) and mild cognitive impairment (MCI) patients are characterized by increased BDNF serum levels. Curr. Alzheimer Res. 7, 15–20. doi: 10.2174/156720510790274473
Balatti, M., Giuli, C., and Conti, F. (2018). Peripheral blood brain-derived neurotrophic factor as a biomarker of Alzheimer’s disease: Are there methodological biases? Mol. Neurobiol. 55, 6661–6672. doi: 10.1007/s12035-017-0866-y
Bathina, S., and Das, U. N. (2015). Brain-derived neurotrophic factor and its clinical implications. Arch. Med. Sci. 11, 1164–1178. doi: 10.5114/ams.2015.56342
Borba, E. M., Duarte, J. A., Bristot, G., Scotton, E., Camozzato, A. L., and Chaves, M. L. F. (2016). Brain-derived neurotrophic factor serum levels and hippocampal volume in mild cognitive impairment and dementia due to Alzheimer disease. Dement. Geriatr. Cogn. Disord. Extra 6, 559–567. doi: 10.1159/000450601
Cheng, Z. (2020). Discussion on related matter of Alzheimers disease. J. Clin. Res. 37, 806–807.
Cheng, Z., Yin, J., Yuan, H., Jin, C., Zhang, F., Wang, Z., et al. (2018). Blood-Derived plasma protein biomarkers for Alzheimer’s disease in Han Chinese. Front. Aging Neurosci. 10:414. doi: 10.3389/fnagi.2018.00414
Brain-derived neurotrophic factor as a useful biomarker to monitor mild cognitive impairment patients?

Rejuvenation Res. 2015;18(4):241-251. doi: 10.1007/s11192-015-9424-2

E. M. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 44, 1239-1246. doi: 10.1212/WNL.44.9.1239

Mori, Y., Tsuji, M., Oguchi, T., Kasuga, K., Kimura, A., Futamura, A., et al. (2021). Serum BDNF as a potential biomarker of Alzheimer's disease: Verification through assessment of serum, cerebrospinal fluid, and medial temporal lobe atrophy. Front. Neurol. 12:653267. doi: 10.3389/fneur.2021.653267

Nascimento, C. M. C., Pereira, J. R., de Andrade, L. P., Garufi, M., Tálib, L. L., Forlenza, O. V., et al. (2014). Physical exercise in MCI elderly promotes reduction of pro-inflammatory cytokines and improvements on cognition and BDNF peripheral levels. Curr. Alzheimer Res. 11, 799-805. doi: 10.2174/156720511034109140102849

Ng, T. K. S., Coughlan, C., Heyn, P. C., Tagawa, A., Carollo, J. J., Kua, E. H., et al. (2021). Increased plasma brain-derived neurotrophic factor (BDNF) as a potential biomarker for and compensatory mechanism in mild cognitive impairment: A case-control study. Aging 13, 22666–22689. doi: 10.18632/aging.203598

Ng, T. K. S., Ho, C. S. H., Tam, W. W. S., Kua, E. H., and Ho, R. C. M. (2019). Decreased serum brain-derived neurotrophic factor (BDNF) levels in patients with Alzheimer's disease (AD): A systematic review and meta-analysis. Int. J. Mol. Sci. 20:257. doi: 10.3390/ijms20020257

O'Byrnett, S. E., Hobson, V. L., Hall, J. R., Barber, R. C., Zhang, S., Johnson, L., et al. (2011). Serum brain-derived neurotrophic factor levels are specifically associated with memory performance among Alzheimer's disease cases. Dement. Geriatr. Cogn. Disord. 31, 31–36. doi: 10.1159/000321980

Pan, W., Banks, W. A., Fasold, M. B., Bluth, J., and Kastin, A. J. (1998). Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37, 1553–1561. doi: 10.1016/S0022-3531(98)00145-5

Petersen, R. C., Smith, G. E., Waring, S. C., Iyengar, R. J., Tangalos, E. G., and Kokmen, E. (1999). Mild cognitive impairment—Clinical characterization and outcome. Arch. Neurol. 56, 303–308. doi: 10.1001/archneur.56.3.303

Popova, N. K., and Naumenko, V. S. (2019). Neuronal and behavioural plasticity: The role of serotonin and BDNF systems tandem. Exp. Opin. Ther. Target 23, 227–239. doi: 10.1080/200228222019.1572747

Qin, X. Y., Cao, C., Cawley, N. X., Liu, T. T., Yuan, J., Loh, Y. P., et al. (2017). Decreased peripheral brain-derived neurotrophic factor levels in Alzheimer's disease. A meta-analysis study (N=7277). Mol. Psychiatry 22, 312–320. doi: 10.1038/mp.2016.62

Rehman, S. H., Lim, S. M., Neoh, C. F., Majeed, A. B. A., Chin, A.-V., Tan, M. P., et al. (2020). Proteomics as a reliable approach for discovery of blood-based Alzheimer’s disease biomarkers: A systematic review and meta-analysis. Aging Res. Rev. 60:101066. doi: 10.1016/j.arrv.2020.101066

Suidea, J., Patloul-Ogiewa, M., Zmuda, W., Targosz-Gajniak, M., Niewiadomska, E., Matuszek, I., et al. (2017). Cognitive impairment and BDNF serum levels. Psychiatr. Neurol. Pol. 51, 24–32. doi: 10.1016/j.pjnp.2016.10.001

Sonali, N., Tripathi, M., Sagar, R., and Vivekanandhan, S. (2013). Val66Met polymorphism and BDNF levels in Alzheimer's disease patients in North Indian population. Int. J. Neurosci. 123, 409–416. doi: 10.3109/00207454.2012.762155

Song, J.-H., Yu, J.-T., and Tan, L. (2015). Brain-derived neurotrophic factor in Alzheimer's disease: Risk, mechanisms, and therapy. Mol. Neurobiol. 52, 1477–1493. doi: 10.1007/s12035-014-9858-4

Tang, T., Zhao, Y., and Yang, X. R. (2020). Correlations between the serum levels of Irisin, FNDCS, BDNF and cognitive function in patients with Alzheimer's disease. J. Trop. Med. 20, 825–828.

Wang, H. B. M. U., Shu, L. S., Tian, C., and Zhang, H. (2000). Validity and reliability of the Chinese version of the Alzheimer's disease assessment scale. Int. Ment. Health J. 8, 89–93.

Wang, S., Zheng, W. N., Chu, H. S., Sheng, X. N., Sun, W. L., Wang, B. B., et al. (2015). Change and its significance of serum levels of brain-derived neurotrophic factor in patients with Alzheimer disease. J. Brain Nerv. Dis. 3, 176–179.

Woolley, J. D., Strobl, E. V., Shelly, B. W., Karydas, A. M., Ketelle, R. N. R., Wolkowitz, O. M., et al. (2012). BDNF serum concentrations show no relationship with diagnostic group or medication status in neurodegenerative disease. Curr. Alzheimer Res. 9, 815–821. doi: 10.2174/1567205128024053595

Wu, Y., Xu, W. W., Cheng, Z. H., Wu, B. L., and Zhou, X. Q. (2016). Brief Elderly cognitive screening inventory: Development, reliability and validity. Chin. J. Gerontol. 36, 1211–1213.

Xie, B., Zhou, H., Liu, W. Y., Wu, L. L., Zuo, J., Jiang, L., et al. (2020). Evaluation of the diagnostic value of peripheral BDNF levels for Alzheimer's disease and mild cognitive impairment: Results of a meta-analysis. Int. J. Neurosci. 130, 218–230. doi: 10.1080/00207454.2019.1667794
Yiannopoulou, K. G., and Papageorgiou, S. G. (2020). Current and future treatments in Alzheimer disease: An update. J. Cent. Nerv. Syst. Dis. 12.1179573520907397.

Zhang, C., Guo, W., Yang, Y., Qin, D., and Liao, X. (2019). Changes in serum brain-derived neurotrophic factor levels in patients with Alzheimer’s disease. Chin. J. Geriatr. 38, 151–154.

Zhao, J.P. and Zheng, Y.P (1992). Reliability and validity of Hamilton depression scale assessed in 329 Chinese depression patients. Chin. Ment. Health J. 5, 214–216.

Zhao, X., and Li, X. (2020). The prevalence of Alzheimer’s disease in the Chinese Han population: A meta-analysis. Neurol. Res. 42, 291–298. doi: 10.1080/01616412.2020.1716467